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Background: The “Patients’ Rights and End of Life Care” Act came into force in France in 2005. It allows
withholding/withdrawal of life-support treatment, and intensified use of medications that may hasten death
through a double effect, as long as hastening death is not the purpose of the decision. It also specifies the
requirements of the decision-making process. This study assesses the situation by examining the frequency of
end-of-life decisions by patients’ and physicians’ characteristics, and describes the decision-making processes.
Methods: We conducted a nationwide retrospective study of a random sample of adult patients who died in
December 2009. Questionnaires were mailed to the physicians who certified/attended these deaths. Cases were
weighted to adjust for response rate bias. Bivariate analyses and logistic regressions were performed for each
decision.
Results: Of all deaths, 16.9% were sudden deaths with no information about end of life, 12.2% followed a decision
to do everything possible to prolong life, and 47.7% followed at least one medical decision that may certainly or
probably hasten death: withholding (14.6%) or withdrawal (4.2%) of treatments, intensified use of opioids and/or
benzodiazepines (28.1%), use of medications to deliberately hasten death (i.e. not legally authorized) (0.8%), at the
patient’s request (0.2%) or not (0.6%). All other variables held constant, cause of death, patient's age, doctor’s age
and specialty, and place of death, influenced the frequencies of decisions. When a decision was made, 20% of the
persons concerned were considered to be competent. The decision was discussed with the patient if competent in
40% (everything done) to 86% (intensification of alleviation of symptoms) of cases. Legal requirements regarding
decision-making for incompetent patients were frequently not complied with.
Conclusions: This study shows that end-of-life medical decisions are common in France. Most are in compliance
with the 2005 law (similar to some other European countries). Nonetheless, the study revealed cases where not all
legal obligations were met or where the decision was totally illegal. There is still a lot to be done through medical
education and population awareness-raising to ensure that the decision-making process is compatible with current
legislation, the physician's duty of care and the patient’s rights.* Correspondence: pennec@ined.fr
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The annual number of deaths in France, ranging between
500,000 and 600,000, has varied relatively little since
World War II, with the decline in mortality rates being
offset by population growth. However, as the large post-
war cohorts grow older, the numbers of deaths will in-
crease considerably (to 770,000 by 2050). Whereas just
after World War II most people died at home, in France,
as in other developed countries, most now die in hospital.
These changes are bound to affect the way death is seen
and experienced, and to influence future health policy and
medical practices. As medical progress increasing-
ly prolongs the life expectancy of the chronically ill, end-
of-life questions such as place of death, palliative
care, decisions to withdraw or reduce active treatment,
staff resources, the role of the family in end-of-life care
and demand for euthanasia are becoming ever more
critical.
End-of-life legal provisions vary widely across Europe.
In France, the Act of 22 April 2005 on Patients’ Rights
and End-of-Life Care [1] introduced three main mea-
sures: Firstly, it prohibits “unreasonable obstinacy” and
therefore the continuation of futile medical treatments.
Secondly, it strengthens the right of access to palliative
care for any person whose condition requires such care,
and recognizes that, under certain conditions, pain and
symptom relief may require drugs that, at high doses,
may have the unintended effect of shortening the
patient’s life. Thirdly, it strengthens the principle of pa-
tient autonomy and of discussion with the patient. If
the patient is not competent, the end-of-life medical
decision must be taken after discussion with a trusted
third party or surrogate (if the patient has named one),
and the family, if any, and after consultation with med-
ical staff or colleagues.
Nevertheless, legalising euthanasia remains a highly
controversial topic in the public and political arena, as
seen during the 2012 presidential election.
In Europe, various surveys [2-5] have shown that in
order to better understand end-of-life conditions, it is
important to study the medical decisions taken prior to
death. In France, the only surveys on end-of-life deci-
sions conducted until now focused on deaths in hospital
or emergency wards [6-9]. The survey Fin de Vie en
France (“End of life in France”), conducted in 2010, con-
cerned all deaths, regardless of cause or place (hospital,
home, nursing home. . .). It provides an overview of end-
of-life care in France that can be used as a baseline for
assessing future developments.
This paper focuses on the medical decisions relating to
end-of-life care in France. It looks at how the decisions
varied according to the person's and physician's charac-
teristics. It also investigates the extent to which these
decisions comply with the 2005 law.Methods
Retrospective survey of physicians
As in previous European surveys [10], we conducted a
retrospective survey on a sample of deaths where the
respondents were the certifying physicians.
This sample of 14,999 deaths was selected by Inserm-
CepiDc (Centre d’épidémiologie sur les causes médicales
de décès) using a systematic random procedure. We
ensured that it was representative (in terms of age, sex,
place of death and region of death) of the 47,872 persons
aged 18 and over who died in France in December 2009.
Stratification by cause of death (a proxy for the likeli-
hood of an end-of-life decision) was not possible because
of the delay in registration of causes of death.
For each death, we identified the certifying physicians
on the death certificates and we mailed them the ques-
tionnaire with instructions for replying. Physicians could
respond either by post (with paid-reply envelope) or on-
line. These two response channels involved trusted third
parties (virtual for Internet responses) to ensure medical
confidentiality with regard to the deceased and the ano-
nymity of both the deceased persons and the physicians
taking part in the study [11]. Three follow-up letters
were sent and a follow-up phone call was made.
We also conducted a telephone survey on a sample of
620 non-responding physicians to ensure that the results
were representative. We recorded their socio-demographic
profiles and their reasons for non-response.
Questions and variables
The questionnaire was based on the Eureld survey ques-
tionnaire [10] but was adapted to take account of the
French legal context and of the results of preliminary
tests. It comprised 113 questions (see Additional file 1).
End-of-life medical decisions and the decision-making
process were explored in the middle part of the ques-
tionnaire after questions about the end-of-life context
(characteristics of the deceased person, physician, place
of death, whether palliative care had been provided). An-
other section comprised questions on the physician's
feelings about the death. The last section asked the phy-
sicians whether they habitually respond to surveys and
what made them decide to respond to this particular sur-
vey if such was the case.
The key questions about end-of-life medical decisions
were (see Additional file 2) (1) whether first of all every-
thing was done to prolong the patient’s life (2) whether a
treatment of any kind was withheld; (3) whether a treat-
ment of any kind was withdrawn; (4) whether a treatment
to alleviate the symptoms was intensified (opioids, benzo-
diazepines and/or any other treatment) and (5) whether a
medication was administered to the patient to deliber-
ately end his/her life. For questions (2) to (4), three sub-
questions investigated the physician's intention: (a) did
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death (b) did he/she take the decision with the explicit
intention of hastening the death and (c) did he/she
consider the decision to have hastened the death. We
classified the answers to these questions to ensure
maximum similarity with the EURELD classification of
medical end-of-life decisions (as published in Van den
Heide [4]): when one of questions (2) (3) and one of
their sub-questions (a) (b) were answered yes, the case
was classified as “non treatment decision”; when ques-
tion (4) and one of its sub-questions (a) (b) were
answered yes, the case was classified as “intensification
of alleviation of symptoms with possible life shortening
effect”; when question (5) was answered yes, we classi-
fied the case as “using a medication to deliberately
hasten death”, differentiating between treatment at the
patient’s explicit request, administration by the patient
him/herself in “physician-assisted suicide” or adminis-
tration by a nurse or a physician. When questions
(2) to (5) were answered no and question (1) was
answered yes, the case was classified as “life-prolonging
decision”; when questions (1) and (5) were answered no
and the sub-questions (a) or (b) to questions (2) (3) (4)
were answered no, we classified the case as “no decision”.
When questions (2), (3) or (4) were answered “yes” and
sub-questions (a) and (b) were answered “no” or “miss-
ing”, the case was classified as “medical decision without
any intention regarding death”.
When more than one question (1) to (5) had been
answered yes, the decision with the most explicit
intention took precedence over other decisions. In cases
of similar intention, question (5) took precedence over
question (4), which took precedence over question (3),
which took precedence over question (2).
We define as sudden deaths those deaths that the
physician considered as sudden and unexpected and for
which he/she cannot give any information about the end
of life. Some deaths were qualified as sudden by the
physician, although he/she was able to give information
about end-of-life decisions, and such a decision did exist
in 60% of those cases. We therefore included them in
our study of “non sudden deaths”.
Information on the person's ability to express his/her
wishes was based on what the physician had noted from
his/her discussion of the decision with the person, and
on the reasons put forward for not having had such a
discussion. Some persons were judged not competent to
be involved in a discussion about their wishes, and some
further persons, after taking part in such a discussion,
were judged not competent to appreciate their situation
and/or to decide for themselves. We did not have any
clear information about the persons’ abilities in other
cases. We considered that the remaining persons were
competent.Participation
Among the entire initial sample of 14,999 deaths, 646 of
the certifying physicians could not be identified. No phys-
ician was asked about more than four deaths, even if they
had certified more. In all, 14,080 questionnaires were sent
to 11,828 certifying physicians (of whom 14% had signed
more than one death certificate). 461 questionnaires did
not reach the addressee owing to postal problems or typ-
ing errors; 608 responses did not include a completed
questionnaire (e.g., physician no longer practising or not
the attending physician). 5,217 completed questionnaires
were received, giving an overall participation rate of 40%
[12]. Only a quarter of responses were obtained online
even though respondents were given a full guarantee of
anonymity with both collection modes. The results pre-
sented are based on 4,891 questionnaires since 327 con-
cerned deaths outside the observation period.Quality control and weighting
The characteristics of the 4,891 deaths in the survey are
very close to those of all deaths in December 2009.
There is a slightly higher percentage of deaths in public
hospitals (55% versus 50%) and a correspondingly lower
percentage at home, in private hospitals and retirement
homes. Cancers and infectious diseases are slightly over-
represented, and cardio-vascular diseases and deaths
from external causes are under-represented.
The answers were weighted for non-response bias
according to the number and distribution of the refer-
ence variables used to select the initial sample of death
certificates: age and sex of the deceased, place of death
and region of residence.Statistical analysis
The categorical data were described using frequencies
and percentages. Univariate and bivariate analyses were
tested with the exact Fisher test instead of a standard Chi
square because of the low numbers in some categories. It
tests the relation between a variable and a particular
medical decision, i.e. whether the observed distribution
of a variable for a particular medical decision is different
from cases without this medical decision. Logistic regres-
sions were performed for each medical decision with
more than 150 observed cases, taking into account both
patients' and physicians' characteristics. All tests were
performed at a significance level of 1%. Logistic regres-
sions (not shown) were performed to determine the vari-
ables or characteristics that remain significant, all other
variables held constant. The results section focuses on
the significant effects of these variables. The statistical
analyses were performed using the SAS Version 9.2
statistical software package.
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This survey was approved by the Comité Consultatif
sur le Traitement de l’Information en Matière de
Recherche dans le Domaine de la Santé (CCTIRS) in
January 2010 and authorized by the Commission Nationale
de l’Informatique et des Libertés data protection committee
(CNIL, - authorization No. 1410166 at sitting 2010–107 of
15 April 2010).
Results
End-of-life medical decisions
We had to exclude 168 cases owing to missing data. Sud-
den deaths (n=798) amounted to 16.9% of the total
(Table 1). For 2,252 non-sudden deaths, one or more
decisions were made that possibly or certainly hastenedTable 1 Frequency of all the different end-of-life medical deci
All decisio
Weighted
N Percentage 9
Sudden death 798 16.9
Medical decision without any intention regarding death
Life-prolonging treatment 1513 32
Treatment withheld 325 6.9
Treatment withdrawn 86 1.8
Intensification of treatment to alleviate symptoms
with opioids or benzodiazepines
386 8.2
Intention of treatment to alleviate symptoms with
medications other than opioids or benzodiazepines
199 4.2
None of the above 599 12.7
Medical end-of-life practice that possibly
or certainly hastened death
Treatment withheld 1594 33.7
Knowing that the decision may hasten the death 1526 32.3
With the intention of hastening death 68 1.4
Treatment withdrawn 531 11.2
Knowing that the decision may hasten the death 465 9.8
With the intention of hastening death 66 1.4
Intensification of treatment to alleviate pain
and/or symptoms (opioids/benzodiazepines)
1381 29.2
Knowing that the decision may hasten the death 1324 29.0
With the intention of hastening death 57 1.2
Use of a drug to deliberately end life* 38 0.8
At patient’s request 11 0.2
Sudden deaths: deaths declared “sudden and unexpected” and on which the physic
The weighted percentages are weighted for non-response bias.
All decisions = every affirmative answer to questions about medical decisions.
Most important decision = when more than one decision is observed, the one with
(see classification details in Methods).
* no doctor assisted suicide have been observed.
Missing values: 168.death. For almost half of these deaths, there were two or
more decisions. In 34% of all deaths, a life-prolonging
treatment was withheld; in 11% it was withdrawn. In
29% of cases alleviation of pain and/symptoms was in-
tensified and in 0.8% a medication was administered de-
liberately to hasten death.
Considering only the most important decision for each
death, the proportion of cases with administration of
medication to deliberately hasten death does not change
(0.8% of all deaths). Of these 38 decisions, 11 were at the
patient’s request.
The physician reported increasing opioid and/or
benzodiazepine doses in another 28% of all deaths.
Withdrawal of life-prolonging treatment was decided in
4% of all deaths, and life-prolonging treatment wassions
ns Most important decision
data Weighted data
5% Confidence
interval
Unweighted
data N
N Percentage 95% Confidence
interval
15.8-18.0 789 798 16.9 15.8-18.0
30.7-33.4 588 576 12.2 11.3.13.2
6.2-7.6 140 140 3 2.5-3.5
1.4-2.2 15 15 0.3 0.2-0.5
7.4-8.9 252 246 5.2 4.6-5.8
3.6-4.8 97 97 2.1 1.7-2.5
11.7-13.7 571 599 12.7 11.7-13.7
2239 2252 47.7
691 688 14.6 13.6-15.6
31.0-33.6 657 655 13.9 12.9-14.9
1.1-1.8 34 33 0.7 0.5-0.9
202 199 4.2 3.6-4.8
9.0-10.7 162 161 3.4 2.9-3.9
1.1-1.7 40 38 0.8 0.6-1.1
1346 1327 28.1 26.8-29.4
26.7-29.3 1306 1288 27.3 26.0-28.5
0.9-1.5 40 39 0.8 0.6-1.1
0.5-1.1 38 38 0.8 0.5-1.1
0.1-0.4 10 11 0.2 0.1-0.4
ian has no information about the end of life.
the most explicit intention (or awareness) of hastening death
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decisions were made with the explicit intention to has-
ten death in 0.8%, 0.8%, 0.7% of cases, respectively.
In all, considering only the most important medical
decisions, 3.1% of all deaths followed a decision to has-
ten death.
For 12.2% of all deaths, the sole reported medical deci-
sion was doing everything possible to prolong life, and
for 12.7% no decision was made (no decision to do
everything to prolong life and none of the other deci-
sions mentioned in the questionnaire). In 11% of cases a
medical decision without any intention regarding death
was reported.
End-of-life medical decisions by patient's and physician's
characteristics
The pathology (cause of death and incurability) and age
of the deceased were decisive in end-of-life decisions.
The frequency of end-of-life decisions varies from 71%
for cancer to 41% for cardio-vascular diseases. For cancer
patients, 3 in 4 end-of-life medical decisions consisted of
intensifying alleviation of symptoms; for respiratory dis-
eases, end of life decisions were more diverse, with in-
tensification of alleviation of symptoms in 40% of cases
and withholding a treatment in 50%. It is difficult to in-
terpret the variations in administration of a drug to de-
liberately end life owing to the small numbers concerned
(Table 2).
The medical decision to withhold a treatment increases
steadily with age from 9.4% with the youngest patients to
22% with the oldest. Conversely, implementation of life-
prolonging treatments declines with age, from 24.8% to
11.3%. For patients aged over 50, intensification of allevi-
ation of symptoms varies little with age.
The frequencies of the different decisions by respond-
ent physicians' characteristics are shown in Table 3. The
patient’s pathology and the number of deaths certified in
the previous three months were directly linked to physi-
cian’s speciality: 46% of cancer specialists certified more
than 10 deaths in the previous three months compared
with 10% of general practitioners, cardiologists and sur-
geons. Logistic regressions (detailed results not shown)
confirm and clarify the decisive influence of the patient’s
pathology on the end-of-life decisions made. All other
variables held constant, physicians involved in the care
of cancer patients reported significantly less often that
they had “done everything possible to prolong life”. They
more often withheld treatment than those treating other
pathologies (except cardio-vascular and digestive dis-
eases), and more often intensified the alleviation of
symptoms. The age of the patient does not seem to be a
determinant for the type of end-of-life decision (non-
treatment decisions or intensifying the alleviation of
symptoms). However, the older the patients, the lessfrequent the decision to do everything possible to pro-
long life. Lastly, there is little differentiation by physi-
cian’s speciality, except for anaesthesiologists and
intensivists and emergency physicians, who were more
likely to do everything possible to prolong life, and can-
cer specialists who were more likely to intensify the alle-
viation of symptoms. Young physicians seem to be less
likely to do everything possible to prolong life and are
more likely to intensify the alleviation of symptoms.
End-of-life decisions are more likely to be made in hos-
pital than at home.
Characteristics of the decision-making process
We have exploitable information about how and why the
decision was made only for cases where the end-of-life
decision and life-prolonging treatment matches the last
affirmative answer to questions (1) to (5), i.e. in 91% of
cases.
When such a decision was made, 1,706 persons were
judged not competent (66% of all decisions) and in 13%
of case we had no information about the persons’ com-
petence. We considered that the remaining 545 persons
were competent. (21%)
In 70% of the cases, when an end-of-life decision was
made, the persons, when competent, were involved in
the discussion. The greater the likelihood that the deci-
sion made by the physician would hasten death, the
more frequently he/she discussed it with the patient, if
competent (see Table 4).
According to the responding physicians, when an end-
of-life decision or an explicit life-prolonging decision
was made, 16% of persons had expressed at some point a
wish to hasten death, although only 1.7% had explicitly
requested euthanasia. The decision was made at the
patient's explicit request in almost 15% of cases. The
greater the likelihood that the decision would hasten
death, the higher the percentage of persons who had
expressed a wish to hasten death (from 8% for those with
a treatment withheld to 38% for those with a medication
given to deliberately hasten death) or who requested eu-
thanasia (0.5 to 17%).
When an end of life decision or an explicit life-
prolonging decision was made and when the patient was
incompetent, 1.5% of the persons had expressed their
wishes through written advance directives. For the
responding physicians, these advance directives were an
important part of the decision in 72% of cases. 50% of
patients had appointed a trusted third party, who took
part in discussions about decisions to be made at later
stages of the disease in 90% of cases. The decisions were
discussed in 45% of cases with colleagues and in 31% of
cases with nursing staff members. No such discussion
(either with colleagues and/or nursing staff, and/or
described as a part of a “collective" process) was reported
Table 2 Frequency of all the different medical end-of-life decisions in France by patients’ characteristics (non-sudden
deaths)
Life prolonging
treatment
Withholding
treatment
Withdrawing
treatment
Intensification of
alleviation of
symptoms
Administration of
a medication
to deliberately
hasten death
No decision Total
deaths
n % n % n % n % n % n % n
Gender
Man 302 15.62 335 17.32 105 5.43 641 33.15 20 1.02 531 27.46 1934
Woman 274 13.74 354 17.78 94 4.72 686 34.45 18 0.89 566 28.42 1991
p value 0.0865 0.7323 0.3214 0.4289 0.6790 0.5478
Age
18-49 37 24.82 14 9.41 7 4.71 50 33.62 1 0.56 40 26.89 149
50-69 139 19.79 74 10.52 43 6.11 268 38.08 11 1.63 168 23.87 704
70-79 113 14.63 128 16.63 42 5.46 294 38.20 7 0.90 186 24.17 770
80-89 204 13.05 309 19.79 79 5.06 486 31.13 16 1.04 467 29.92 1561
90+ 83 11.30 163 22.07 29 3.93 227 30.74 2 0.27 234 31.69 738
p value <0.0001 <0.0001 0.4066 0.0003 0.1118 0.0008
Place of death
At home 104 15.60 100 14.96 22 3.29 150 22.44 9 1.37 283 42.34 668
Public hospital 334 15.67 393 18.44 121 5.68 793 37.21 16 0.76 474 22.24 2131
Private hospital 59 14.97 56 14.15 23 5.81 156 39.41 8 1.92 94 23.75 396
Hospice, retirement home 66 9.95 132 19.83 33 4.96 207 31.10 3 0.51 224 33.65 666
Public place, street or other 12 18.90 8 12.43 0 0.00 20 31.08 1 1.85 23 35.74 64
p value 0.0037 0.0124 0.0181 <0.0001 0.1017 <0.0001
Cause of death
Cancer 69 5.57 171 13.76 50 4.02 643 51.73 21 1.68 289 23.25 1243
Cardio-vascular disease 208 24.92 129 15.46 42 5.03 175 20.97 4 0.44 277 33.19 835
Neurological disease 68 11.02 146 23.59 42 6.79 183 29.57 5 0.76 175 28.27 619
Infectious disease 63 21.01 64 21.43 15 5.02 101 33.81 3 0.99 53 17.74 299
Respiratory disease 45 17.29 76 29.37 11 4.25 61 23.57 3 1.17 63 24.35 259
Digestive disease 42 25.77 27 16.53 7 4.29 47 28.78 1 0.75 39 23.88 163
Mental or psychiatric disorder 7 5.57 24 19.85 10 8.27 38 31.43 1 0.97 41 33.91 121
Other cause 64 19.28 45 13.55 21 6.33 64 19.28 0 0.00 138 41.57 332
. 11 20.26 5 9.49 2 3.80 14 26.58 0 0.00 21 39.87 53
p value <0.0001 <0.0001 0.1918 <0.0001 (0.0728) <0.0001
Incurable disease
Yes 235 9.63 434 17.79 120 4.92 982 40.25 29 1.17 640 26.23 2440
No 303 23.09 224 17.06 72 5.48 319 24.29 9 0.68 386 29.39 1313
. 38 21.92 31 17.78 7 4.05 26 14.82 0 0.00 72 41.43 173
p value <0.0001 0.5357 0.5044 <0.0001 0.2138 0.0231
All percentages are weighted for non-response, to ensure there are representative of the initial. The percentage cannot be derived from the absolute unweighted
absolute numbers. The p values are obtained with a Fisher exact test. Due to some cells with small numbers, some assumptions of a chi2 test are complied with.
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Table 3 Frequency of all the different medical end-of-life decisions in France by physicians' characteristics (non sudden
deaths)
Life prolonging
treatment
Withholding
treatment
Withdrawing
treatment
Intensification
of alleviation
of symptoms
Administration
of a medication
to deliberately
hasten death
No decision Total
deaths
n % n % n % n % n % n %
Gender
Man 414 15.9 452 17.4 123 4.7 822 31.6 29 1.1 758 29.2 2598
Woman 156 12.1 232 18.0 74 5.8 485 37.7 8 0.6 332 25.8 1287
. 6 16.2 4 10.2 2 5.1 20 50.8 0 0.0 7 17.8 39
P value 0.0074 0.4357 0.4072 <0.0001 0.2600 0.0453
Age
Under 40 120 13.8 161 18.4 50 5.7 351 40.2 14 1.5 178 20.4 874
40-49 168 14.9 198 17.6 75 6.7 371 33.0 3 0.3 310 27.5 1125
50-59 200 14.7 237 17.5 56 4.1 424 31.3 14 1.0 424 31.3 1355
60 and over 86 15.8 87 16.0 16 2.9 169 31.1 7 1.2 179 33.0 543
. 3 9.6 5 18.1 2 7.2 11 39.8 0 0.0 7 25.3 28
P value 0.8056 0.8511 0.0049 0.0002 0.0600 <0.0001
Speciality
General practice 142 11.0 229 17.7 47 3.6 410 31.7 13 1.0 450 34.8 1292
Intensive care 136 29.1 58 12.4 58 12.4 147 31.4 5 1.0 64 13.7 468
Oncology 13 7.1 17 9.5 6 3.4 96 53.9 6 3.1 41 23.0 178
Cardiology 32 26.7 26 21.6 1 0.8 34 28.2 5 4.4 22 18.3 120
Surgery 16 24.1 7 10.8 2 3.1 22 34.1 0 0.0 18 27.9 65
Geriatrics 75 8.8 151 17.7 44 5.2 330 38.7 3 0.3 250 29.3 853
Emergency 81 24.4 63 18.9 15 4.5 50 15.0 0 0.0 124 37.2 333
Neurology 2 4.9 9 24.6 1 2.5 16 43.5 0 0.0 9 24.5 37
Other 78 13.9 125 22.2 25 4.4 213 37.9 6 1.0 115 20.5 562
. 1 4.2 3 14.4 2 9.6 11 52.7 0 0.0 4 19.2 21
P value <0.0001 0.0014 (<0.0001) <0.0001 0.0003 <0.0001
Work context
General practice 93 12.2 135 17.7 21 2.8 201 26.4 10 1.3 301 39.5 761
Public hospital 352 17.9 357 18.1 123 6.2 670 34.0 17 0.8 451 22.9 1970
Private hospital 47 16.6 31 11.0 17 6.0 120 42.4 4 1.4 64 22.6 283
Medico-social, rehab. or
LTC establishment
16 6.9 51 21.7 7 3.0 99 42.1 0 0.0 62 26.4 235
Other 20 9.2 30 13.6 11 5.0 78 35.4 2 1.0 79 35.8 221
Several work contexts 44 10.6 77 18.7 19 4.6 138 33.5 4 1.1 130 31.5 412
. 4 9.1 6 14.3 1 2.4 21 50.2 0 0.0 10 23.9 42
P value <0.0001 0.0271 0.0544 <0.0001 (0.5054) <0.0001
Size of agglomeration
<5000 55 8.5 118 18.4 25 3.9 212 33.0 10 1.6 222 34.6 642
5-10000 60 13.8 74 17.1 16 3.7 130 30.0 3 0.8 150 34.7 433
20-20000 72 15.2 84 17.8 20 4.2 153 32.4 5 1.1 138 29.2 472
20-100000 212 17.7 210 17.5 64 5.3 406 33.9 9 0.8 296 24.7 1197
100-200000 56 14.1 75 18.7 29 7.2 130 32.4 2 0.5 109 27.1 402
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Table 3 Frequency of all the different medical end-of-life decisions in France by physicians' characteristics (non sudden
deaths) (Continued)
>200000 107 16.0 110 16.4 41 6.1 256 38.2 6 0.9 150 22.4 670
. 15 13.7 18 16.5 4 3.7 40 36.6 1 1.2 31 28.4 109
P value <0.0001 0.9308 0.0891 0.1108 (0.6023) <0.0001
Number of deaths certified in the past 3 months
0 34 16.8 40 19.5 10 4.9 57 27.8 2 1.1 61 29.8 205
1–2 123 15.0 144 17.6 24 2.9 241 29.4 10 1.2 277 33.8 819
3–4 169 16.0 199 18.8 62 5.9 337 31.9 9 0.9 280 26.5 1056
5–9 149 15.2 156 15.8 50 5.1 354 35.9 8 0.8 269 27.3 986
10–19 60 11.6 100 19.3 34 6.6 202 39.1 5 1.0 116 22.4 517
20+ 18 8.5 28 13.2 15 7.1 94 44.3 0 0.0 57 26.9 212
. 22 17.5 21 16.5 5 3.9 39 30.6 3 2.4 37 29.1 127
P value 0.0534 0.2641 0.0259 <0.0001 (0.4672) 0.0006
In-service training on end-of-life
Yes 197 10.6 311 16.7 101 5.4 712 38.3 10 0.6 526 28.3 1858
No 370 18.7 364 18.3 94 4.7 588 29.6 25 1.2 543 27.4 1984
. 8 10.0 13 15.5 5 5.9 26 30.9 3 3.1 29 34.5 84
All percentages are weighted for non-response, to ensure there are representative of the initial. The percentage cannot be derived from the absolute unweighted
absolute numbers. The p values are obtained with a Fisher exact test. Due to some cells with small numbers, some assumptions of a chi2 test are complied with.
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type of decision: discussions with colleagues, family, or
trusted third party were more frequent when decisions
were more likely to hasten death (Table 4).
When a drug was administered to deliberately hasten
death on the patient’s explicit request, this request was
repeated 8 times out of 11, and an explicit request for
euthanasia was made in 6 cases. When the sole decision
was to prolong life, it was at patient’s explicit request in
4% of the cases.
Among the 55 explicit requests for euthanasia reported
by the physicians, 6 were granted, whereas in 44 cases
the physician chose to intensify the alleviation of symp-
toms, and in 1 case no decision was reported, except for
doing everything possible to prolong the life.
For almost half of the physicians, “deep sedation for
distress in terminal phase” was the term that best
described the decision to deliberately administer a medi-
cation to hasten death; much less frequently “symptom
treatment” or “non-treatment decision”. Only 5 physi-
cians reported “euthanasia”.
Discussion and conclusions
Main findings
For the first time, this study provides data on end-of-
life medical decisions on a representative sample of all
deaths in France.
In 12.2% of cases, the decision was to do everything
possible to prolong life. Non-treatment decisions were
made in 16.8% of cases, treatment was withheld in 14.6%
and withdrawn in 4.2%. Alleviation of symptoms withopioids and/or benzodiazepines was intensified in 28.1%
of cases, A drug was administered to deliberately hasten
death in 0.8% of cases, at the patient's request in 11 out
of the 38 cases concerned.
The study shows that end-of-life medical decisions that
may hasten death are relatively frequent in France. Most
of such decisions are in compliance with the law, which
allows physicians to withhold or withdraw life prolonging
treatment and to intensify alleviation of symptoms even if
unintended side effects may hasten death (“double effect”),
as long as the first intention is not to hasten death. In a
much smaller number of cases (3.1%), the death followed a
decision made with the declared intention of hastening
death. The patient's pathology is the main factor governing
this type of decision. Even though most end-of-life medical
decisions are made in compliance with the 2005 law, and
decisions leading to a strong likelihood of death are more
frequently taken after discussion with the patient or
trusted third party and the medical staff (other doctors,
nursing staff ), the study shows that the legal provisions
governing these decisions are not always fully respected.Strengths and limitations
For the first time in France, this study provides data on
end-of-life decisions on a representative sample of
deaths, whatever the cause, wherever the death took
place. It gives objective results on this important issue
that will inform and assist both public and legislative de-
bate. The French national end-of-life watchdog Observa-
toire National de la Fin de Vie (ONFV) has noted the
Table 4 Characteristics of decision-making by type of medical decision (non sudden deaths)
Life prolonging
treatment
Withholding
treatment
Withdrawing
treatment
Intensification
of alleviation
of symptoms
Administration
of a medication
to deliberately
hasten death
n % n % n % n % n %
Decision discussed with patient (by respondent or other physician)
Yes 55 9.6 40 8.02 12 8.63 263 19.82 6 16.18
No 79 13.7 40 8.02 3 2.16 44 3.32 2 6.31
Patient not competent 308 53.6 357 71.54 112 80.55 904 68.12 25 67.40
Don't know 19 3.3 6 1.20 3 2.19 26 1.96 1 3.46
No response 114 19.8 56 11.22 9 6.47 90 6.78 2 6.65
Discussion, per 100 competent patients 41.0 50.0 80.0 85.7 71.9
Decision following patient's explicit request
Yes and request repeated 14 2.43 20 4.03 9 6.39 166 12.50 8 21.00
Yes and request not repeated 4 0.69 5 1.01 1 0.62 41 3.09 2 5.85
Yes and do not know whether request repeated 7 1.22 7 1.41 0 0.00 40 3.01 1 2.63
No 418 72.57 392 79.03 117 83.06 962 72.44 22 58.92
No response 133 23.09 72 14.52 14 9.94 119 8.96 4 11.60
Patient expressed wish at some moment to hasten death
Yes 13 2.26 46 9.26 14 10.00 203 15.31 14 38.35
No 333 57.81 261 52.52 86 61.43 809 61.01 11 28.99
Do not know 115 19.97 126 25.35 30 21.43 210 15.84 10 27.30
No response 115 19.97 64 12.88 10 7.14 104 7.84 2 5.36
Decision discussed with another person
incompetent person
Doctors 102 33.12 136 38.10 62 55.36 434 48.01 14 56.00
Nurses and nursing assistants, medical care team 49 15.91 95 26.61 42 37.50 326 36.06 10 40.00
Family 74 24.03 171 47.90 64 57.14 549 60.73 19 76.00
Other people 1 0.32 3 0.84 0 0.00 4 0.44 0 0.00
Trusted third party 19 6.17 29 8.12 15 13.39 150 16.59 5 20.00
As part of a collective decision 16 5.19 24 6.72 15 13.39 137 15.15 5 20.00
No 119 38.64 48 13.45 4 3.57 57 6.31 1 4.00
No response 7 2.27 8 2.24 1 0.89 11 1.22 0 0.00
Trusted third party
incompetent person
Yes and involved in discussion phase 57 18.51 71 19.89 22 19.64 312 34.55 8 32.00
Yes and not involved in discussion phase 19 6.17 7 1.96 6 5.36 11 1.22 1 4.00
Yes and do not know whether involved or not 4 1.30 2 0.56 1 0.89 3 0.33 0 0.00
No 99 32.14 108 30.25 31 27.68 295 32.67 10 40.00
No because patient not capable of naming one 54 17.53 105 29.41 27 24.11 177 19.60 4 16.00
Do not know 75 24.35 64 17.93 25 22.32 105 11.63 2 8.00
Advance directive
incompetent person
Yes and was an important factor in the decision 1 0.32 2 0.56 0 0.00 9 1.00 2 8.00
Yes and was not important factor in the decision 0 0.00 2 0.56 0 0.00 3 0.33 0 0.00
Yes and do not know whether important factor
in the decision
0 0.00 0 0.00 0 0.00 0 0.00 0 0.00
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Table 4 Characteristics of decision-making by type of medical decision (non sudden deaths) (Continued)
No 185 60.06 233 65.45 75 66.96 685 75.86 16 64.00
Do not know 122 39.61 119 33.43 37 33.04 206 22.81 7 28.00
Best description of the medical act
Symptom treatment 337 58.41 144 28.92 17 12.15 717 54.03 7 19.44
Decision to withhold or withdraw treatment 20 3.47 237 47.59 104 74.31 123 9.27 6 17.06
Sedation for distress in terminal phase 10 1.73 19 3.82 1 0.60 361 27.21 17 45.59
Euthanasia 0 0.00 0 0.00 1 0.79 1 0.07 5 12.04
Medically assisted suicide 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00
Other 66 11.44 30 6.02 6 4.29 18 1.36 0 0.00
No response 144 24.96 68 13.65 11 7.86 107 8.06 2 5.87
All percentages are weighted for non-response, to ensure there are representative of the initial. The percentage cannot be derived from the absolute unweighted
absolute numbers.
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this regard in France [13].
This survey also shows that investigating this sensitive
topic and even exploring illegal practices is possible in
France; this was by no means certain when the study was
first launched. That is why we deliberately adapted the
questionnaire to take account of the French legislative
context and of the French sensitivity on this issue
revealed in preliminary tests, even at the expense of
comparability with other countries.
From a methodological viewpoint, we conducted the
survey using a mixed mode approach, i.e. enabling physi-
cians to answer either by Internet or by returning the
questionnaire in a paid-reply envelope. We developed a
different process for each of the response channels in
order to guarantee total anonymity.
The 40% participation rate is towards the bottom of the
range of the European EURELD surveys and could be con-
sidered as a limitation [4]. One explanation for this low rate
might be that, unlike some of the EURELD surveys with a
higher response rate, we did not stratify the sample accord-
ing to the likelihood that death followed a potential end-of-
life decision, and therefore sent our questionnaire to pro-
portionally more physicians who would probably consider
their patient's end of life to be irrelevant to the survey. But
in fact, this participation rate is fairly close to that for other
surveys of French physicians [7,14]. In the non-response
survey, the main reasons given were lack of time and re-
fusal to take part in any kind of survey. Few doctors men-
tioned the survey topic as a reason for not responding. The
length of the questionnaire and, above all, the need to look
through the patient’s case history may have been dissuasive.
Some doctors did not feel the survey concerned them, es-
pecially if they had not been treating the patient prior to
death, as the under-representation of deaths from external
causes also suggests.
Nevertheless, the comparison of respondent and non-
respondent physicians’ profiles reveals no significantdifferences, lending support to our belief that this assess-
ment of end-of-life medical decisions is likely to be reli-
able, although an under-estimation of illegal practices
cannot be excluded.
This survey, like others on the same topic, [2,4,15-27]
is based on the responses of physicians, who are best
placed to answer questions about decisions for which
they have taken responsibility. However, one limitation is
that they can only report on their own experience of a
reality that also involves other people (the patient, the
family or friends, other medical staff etc.) who might
have different points of view.
Comparison with end-of-life decisions in other studies
The only figures available in France about end-of-life deci-
sions concerned withholding or withdrawal of life support
were conducted in 2004, prior to the law. In the MAHO
survey [28], carried out in public hospitals, withholding or
withdrawing life support was less frequent than in our
results concerning all public hospitals (45.4% of the
deceased patients included in the study, vs. 51.2% in our
survey). In the DALISA survey [8,14], carried out in emer-
gency departments, withholding life support was observed
in 41.5% of the deaths, and withdrawing (alone or preceded
by withholding) life support in 58.5%, vs. 89% and 11% re-
spectively, in our results concerning emergency depart-
ments. These differences may be partially explained by the
different study designs; the legislation has also changed be-
tween these studies and ours.
It is not easy to compare study findings with those con-
ducted elsewhere, even where similar survey protocols are
used (retrospective survey of certifying physicians, with a
representative sample of deaths). The definition we used
for sudden deaths and the wording and approach for ques-
tions about end-of-life medical decisions were different to
those used in EURELD type studies. In particular, we chose
a two-step approach: a question on a treatment/decision
(withholding, withdrawing a treatment, intensifying the
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sible or certain effect on hastening death as well as the
intention of hastening death, is investigated. According to
Seale [29] who compared the two wordings for UK, the
two-step approach gives a lower percentage of end-of-life
decisions compared to the approach where the potential
effect of hastening death is included in the question of
treatment. As a result, end-of-life decisions could not be
classified in an identical manner as Eureld, although we
tried to get as close as possible. If we had replaced our def-
inition of “sudden death” (deaths declared by physician as
“sudden and unexpected” and for which they cannot pro-
vide any information about the patient's end of life) with
the EURELD definition, the percentage of sudden deaths
would have more than doubled (from 16.9 to 39.3%). This
change of definition of sudden deaths reduces more the
proportion of medical decisions without any intention
regarding deaths than the one that possibly or certainly
hastened deaths.
Compared with the 2001 Eureld survey results
[4] and more recent results in Belgium [30] and the
Netherlands [31], and taking the definitions of medical deci-
sions closest to those used in these surveys, the proportion
of sudden deaths in the French data (39%) is higher than
that of all other countries (29-34%). The percentage of
deaths for which a decision was made that possibly or
certainly hastened death (40%), is around the average
observed in the other European countries. It is much higher
than in Italy, (29% in 2001), but well below the levels in
Switzerland, where assisted suicide is legal (51% in 2001),
and in the Netherlands (57% in 2010) and Belgium (48% in
2007), two countries where euthanasia has been legalised.
In France, intensification of treatment to alleviate pain and/
or symptoms is close to the level observed in Belgium in
2007, but slightly higher than in most EURELD countries.
However, levels of withholding or withdrawal of treatment
are similar to those observed in more recent surveys in Bel-
gium and the Netherlands.
France ranks among the countries with a low percent-
age of physician-assisted dying by administration of a
drug to deliberately hasten death. At less than 1%, this
level is close to the Danish level in 2001, it is higher
than in Sweden and Italy and much lower than in the
Netherlands and Belgium. No physician-assisted suicide
was reported and euthanasia (at the patient’s request) is
very rare. According to our results, a fifth of medical
decisions that possibly or certainly hastened deaths are
made at the patient’s request, (a third for deaths with a
decision to administer a medication to deliberately has-
ten death). This is much lower than in the Netherlands
and Belgium (where Euthanasia is legal). It is higher than
in other European countries in the 2001 Eureld survey.
Discussion of the decision with competent patients was
more frequent in France (80%) than in most Europeancountries in 2001 with the exception of the Netherlands.
Also for non-competent patients, the family is very often
involved in the discussion (78%), less frequently than in
the Netherlands, similarly to Belgium-Switzerland but
much more frequently than in other countries. This
might reflect an effect of the French law on discussion
with patients or relatives.
Overall, the main results on end-of-life medical deci-
sions are consistent with those of surveys conducted in
other countries: intensification of pain relief treatment is
the most common decision [17] and administration of
drugs to intentionally end the patient’s life is rare.
Discussion of the findings in light of the French law
In France, the 2005 law on patients’ rights and the end of
life defined a legal framework allowing patients to refuse
any treatment they consider unreasonable, and allowing
doctors to decide on treatments that may have the side ef-
fect of hastening death, in accordance with the wishes
expressed by the patient [1]. The medical decisions
observed in our survey mostly complied with French legal
requirements, as the 2005 Act allows withholding and with-
drawal of life support, and intensified alleviation of symp-
toms even when it may (unintentionally) hasten death.
Indeed 80% of the physicians who made this decision said
they were aware of its potential “double effect”. Some deci-
sions overstepped the law, although very rarely. A drug was
administered with the explicit intention of hastening death
– an act that can be considered as poisoning under French
law – at the patient's explicit request in 0.2% of these
deaths, and without a clear patient request in another 0.6%.
Intention to hasten death was also declared, even if very in-
frequently, in some of the decisions of life support with-
holding or withdrawal or of intensified alleviation of
symptoms. As a whole, decisions with intention to hasten
death amounted to 3.1% of all deaths, and only one out five
of these decisions was made on the patient's explicit re-
quest, whereas such a request is mandatory in all countries
where the law permits euthanasia in specific cases, and is
part of the ONFV definition of euthanasia [1].
The decision making processes observed in our survey
were far from complying with the 2005 legal procedures,
which are required whatever the end-of-life decision
made. A discussion with the patient when competent
was mentioned by the physician in only 72% of the cases
when a drug was administered intentionally to hasten
death, in 80% when life support was withdrawn, and 41%
when everything was done to prolong life.
When an end-of-life decision is made for an incompe-
tent patient, advance directives if any, discussion with a
trusted third party previously named by the patient, if
any, discussion with the family, if any, discussion with a
colleague not in charge of the patient, with colleagues
and with nursing staff members, are compulsory
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treatment was withdrawn for a possibly incompetent pa-
tient, the decision was discussed with other doctors in
39% of cases, with the nursing staff in 27% of cases and
with the family in 50% of cases. The physician made this
decision alone in 14% of cases. When a drug was admi-
nistered with the intention of hastening death, the deci-
sion was discussed in 14, 10, 19 and 4 cases out of 24,
respectively.
Looking at these discrepancies between legal require-
ments and actual practice, we should not forget that our
survey concerned deaths that occurred in December
2009, less than three years after the revision of the med-
ical ethics charter. There is still a lot to be done through
medical education and population awareness-raising to
ensure that no physician is obliged to face such difficult
decisions alone.
Conclusion
In conclusion, these results provide an overview of end-of-
life medical decisions in France, three years after the 2005
regulations were enacted, and for the first time on a large
sample representative of all kinds of deaths. They are ob-
jective results in the context of the current legislation.
They will help medical authorities and policy makers to
examine how the act of parliament is applied and to
understand more clearly which features of the current law
are difficult to comply with. They will inform and assist
the current public debate on this important topic. They
will also serve as a baseline to investigate future changes.
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